Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Josef Thaler

Showing results (41-50 of 72) with videos related to

Pageof 8
Sort By:
Critical Reviews in Oncology/Hematology|September 10, 2011
Nilotinib as frontline and second-line therapy in chronic myeloid leukemia: open questionsPeter Valent, Günther Gastl, Klaus Geissler, et al.
Wiener Klinische Wochenschrift|January 1, 2009
Diagnostic algorithms, monitoring, prognostication, and therapy in chronic myeloid leukemia (CML): a proposal of the Austrian CML platformPeter Valent, Thomas Lion, Dominik Wolf, et al.
Journal of Geriatric Oncology|September 30, 2023
Quality of life, effectiveness, and safety of aflibercept plus FOLFIRI in older patients with metastatic colorectal cancer: An analysis of the prospective QoLiTrap studyGudrun Piringer, Josef Thaler, Sandro Anchisi, et al.
Breast Cancer Research and Treatment|July 29, 2008
The Austrian fulvestrant registry: results from a prospective observation of fulvestrant in postmenopausal patients with metastatic breast cancerRupert Bartsch, Brigitte Mlineritsch, Michael Gnant, et al.
Cancer Medicine|November 12, 2018
Supervised versus autonomous exercise training in breast cancer patients: A multicenter randomized clinical trialTheresa Westphal, Gabriel Rinnerthaler, Simon Peter Gampenrieder, et al.
Scientific Reports|September 18, 2023
Real world evidence reveals improved survival outcomes in biliary tract cancer through molecular matched targeted treatmentBernhard Doleschal, Hossein Taghizadeh, Gerald Webersinke, et al.
Anticancer Research|November 5, 2014
Preoperative treatment with capecitabine, cetuximab and radiotherapy for primary locally advanced rectal cancer--a phase II clinical trialWolfgang Eisterer, Alexander De Vries, Dietmar Öfner, et al.
British Journal of Cancer|October 21, 2016
Impact of tumour RAS/BRAF status in a first-line study of panitumumab + FOLFIRI in patients with metastatic colorectal cancerMeinolf Karthaus, Ralf-Dieter Hofheinz, Laurent Mineur, et al.
Anticancer Research|January 1, 2015
Lapatinib-plus-pegylated liposomal doxorubicin in advanced HER2-positive breast cancer following trastuzumab: a phase II trialMagdalena Pircher, Brigitte Mlineritsch, Michael A Fridrik, et al.
Frontiers in Oncology|August 25, 2023
LM02 trial Perioperative treatment with panitumumab and FOLFIRI in patients with wild-type RAS, potentially resectable colorectal cancer liver metastases-a phase II studyGudrun Piringer, Thomas Gruenberger, Josef Thaler, et al.
Pageof 8

Showing results (41-50 of 72) with videos related to

Sort By:
Pageof 8
Critical Reviews in Oncology/Hematology|September 10, 2011
Nilotinib as frontline and second-line therapy in chronic myeloid leukemia: open questionsPeter Valent, Günther Gastl, Klaus Geissler, et al.
Wiener Klinische Wochenschrift|January 1, 2009
Diagnostic algorithms, monitoring, prognostication, and therapy in chronic myeloid leukemia (CML): a proposal of the Austrian CML platformPeter Valent, Thomas Lion, Dominik Wolf, et al.
Journal of Geriatric Oncology|September 30, 2023
Quality of life, effectiveness, and safety of aflibercept plus FOLFIRI in older patients with metastatic colorectal cancer: An analysis of the prospective QoLiTrap studyGudrun Piringer, Josef Thaler, Sandro Anchisi, et al.
Breast Cancer Research and Treatment|July 29, 2008
The Austrian fulvestrant registry: results from a prospective observation of fulvestrant in postmenopausal patients with metastatic breast cancerRupert Bartsch, Brigitte Mlineritsch, Michael Gnant, et al.
Cancer Medicine|November 12, 2018
Supervised versus autonomous exercise training in breast cancer patients: A multicenter randomized clinical trialTheresa Westphal, Gabriel Rinnerthaler, Simon Peter Gampenrieder, et al.
Scientific Reports|September 18, 2023
Real world evidence reveals improved survival outcomes in biliary tract cancer through molecular matched targeted treatmentBernhard Doleschal, Hossein Taghizadeh, Gerald Webersinke, et al.
Anticancer Research|November 5, 2014
Preoperative treatment with capecitabine, cetuximab and radiotherapy for primary locally advanced rectal cancer--a phase II clinical trialWolfgang Eisterer, Alexander De Vries, Dietmar Öfner, et al.
British Journal of Cancer|October 21, 2016
Impact of tumour RAS/BRAF status in a first-line study of panitumumab + FOLFIRI in patients with metastatic colorectal cancerMeinolf Karthaus, Ralf-Dieter Hofheinz, Laurent Mineur, et al.
Anticancer Research|January 1, 2015
Lapatinib-plus-pegylated liposomal doxorubicin in advanced HER2-positive breast cancer following trastuzumab: a phase II trialMagdalena Pircher, Brigitte Mlineritsch, Michael A Fridrik, et al.
Frontiers in Oncology|August 25, 2023
LM02 trial Perioperative treatment with panitumumab and FOLFIRI in patients with wild-type RAS, potentially resectable colorectal cancer liver metastases-a phase II studyGudrun Piringer, Thomas Gruenberger, Josef Thaler, et al.
Pageof 8